SYL1001 (Tivanisiram), 11.25 mg/ml one drop q.d. for 28 days, silences the vanilloid receptor 1 (TRPV1) to treat dry eye syndrome 262, 263. This evidence concerns the gene TRPV1 and dry eye syndrome.